Editas Medicine, Inc.

EDIT

$263M

Micro Cap

NASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaCAMBRIDGE226 employees

Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Aug 11, 2026

Market Overview

Stock performance and key metrics

EDIT News

Catalyst Timeline

1 upcoming, 0 past

EarningsNext

EDIT Earnings Report

Aug 11, 2026Confirmed

EPS Est: $-0.30 | FQ end 2026-06

How EDIT's past catalysts played out

earningsMay 2024-11%earningsFeb 2024+25%earningsNov 2023+18%earningsAug 2023+6%earningsMay 2023+12%earningsFeb 2023+6%earningsAug 2022+13%earningsMay 2022+11%

Drug Pipeline

No drugs found in this phase.

📑

Catalyst DossierPRO

The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.

→

Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move

Regulatory Approvals

Frequently asked questions

When is Editas Medicine, Inc.'s next FDA catalyst?→

Editas Medicine, Inc.'s (EDIT) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track EDIT biotech catalysts?→

Add EDIT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Editas Medicine, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply